Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-escalation study of hrBMP4 by convection-enhanced delivery in recurrent glioblastoma
NL-OMON46932Phase 1Active, not recruiting
- Sponsor
- StemGen
- Start
- Jul 2017
- Modality
- Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bone morphogenetic protein 4 in glioblastoma (GBM), sponsored by StemGen. Primary endpoints: Feasibility and safety, Dose-limiting toxicity and 1 more. Started Jul 2017; status: active, not recruiting.
02
Drugs
bone morphogenetic protein 4
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON46932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46932.